Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

被引：0
|
作者：
David Schnell
Susanne Buschke
Holger Fuchs
Dietmar Gansser
Rainer-Georg Goeldner
Martina Uttenreuther-Fischer
Peter Stopfer
Sven Wind
Marc Petersen-Sylla
Atef Halabi
Rüdiger Koenen
机构：
[1] Boehringer Ingelheim Pharma GmbH & Co KG,Translational Medicine and Clinical Pharmacology
[2] Boehringer Ingelheim Pharma GmbH & Co KG,Drug Metabolism and Pharmacokinetics
[3] Boehringer Ingelheim Pharma GmbH & Co KG,Global Biometrics and Clinical Applications
[4] Boehringer Ingelheim Pharma GmbH & Co KG,Clinical Development and Medical Affairs
[5] Kiel GmbH,Clinical Research Services (CRS)
来源：
Cancer Chemotherapy and Pharmacology | 2014年 / 74卷
关键词：
Afatinib; Hepatic impairment; Pharmacokinetics; Human; Epidermal growth factor receptor (EGFR); Tyrosine kinase inhibitor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：267 / 275
页数：8
相关论文
共 50 条
  • [1] Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
    Schnell, David
    Buschke, Susanne
    Fuchs, Holger
    Gansser, Dietmar
    Goeldner, Rainer-Georg
    Uttenreuther-Fischer, Martina
    Stopfer, Peter
    Wind, Sven
    Petersen-Sylla, Marc
    Halabi, Atef
    Koenen, Ruediger
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (02) : 267 - 275
  • [2] Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment
    Frost, Charles E.
    Ly, Van
    Garonzik, Samira M.
    [J]. DRUGS IN R&D, 2021, 21 (04) : 375 - 384
  • [3] Pharmacokinetics of sirolimus (rapamycin) in subjects with mild to moderate hepatic impairment
    Zimmerman, JJ
    Lasseter, KC
    Lim, HK
    Harper, D
    Dilzer, SC
    Parker, V
    Matschke, K
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (12): : 1368 - 1372
  • [4] Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment
    Charles E. Frost
    Van Ly
    Samira M. Garonzik
    [J]. Drugs in R&D, 2021, 21 : 375 - 384
  • [5] Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment
    Desai, Amit
    Schmitt-Hoffmann, Anne-Hortense
    Mujais, Salim
    Townsend, Robert
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (05) : 3025 - 3031
  • [6] The pharmacokinetics of dalbavancin in subjects with mild, moderate, or severe hepatic impairment
    J Dowell
    E Seltzer
    M Buckwalter
    T Marbury
    D Simoneau
    E Boudry
    [J]. Critical Care, 12 (Suppl 2):
  • [7] Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment
    Turncliff, RZ
    Dunbar, JL
    Dong, QM
    Silverman, BL
    Ehrich, EW
    Dilzer, SC
    Lasseter, KC
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (11): : 1259 - 1267
  • [8] Pharmacokinetics of Imeglimin in Subjects with Moderate Hepatic Impairment
    Chevalier, Clemence
    Dubourg, Julie
    Bolze, Sebastien
    Fouqueray, Pascale
    [J]. CLINICAL PHARMACOKINETICS, 2021, 60 (04) : 485 - 490
  • [9] Pharmacokinetics of Imeglimin in Subjects with Moderate Hepatic Impairment
    Clémence Chevalier
    Julie Dubourg
    Sébastien Bolze
    Pascale Fouqueray
    [J]. Clinical Pharmacokinetics, 2021, 60 : 485 - 490
  • [10] Pharmacokinetics of Maribavir in Subjects with Moderate Hepatic Impairment
    Song, I. H.
    Ilic, K.
    Wu, J.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 792 - 792
12345